Pilot Single Arm, Single Center, Open Label Trial of Pembrolizumab in Patients With Intermediate and High Risk Smoldering Multiple Myeloma

Trial Profile

Pilot Single Arm, Single Center, Open Label Trial of Pembrolizumab in Patients With Intermediate and High Risk Smoldering Multiple Myeloma

Active, no longer recruiting
Phase of Trial: Phase 0

Latest Information Update: 03 Apr 2018

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Mar 2018 Planned End Date changed from 1 Jul 2019 to 1 Jul 2021.
    • 26 Mar 2018 Planned primary completion date changed from 1 Jul 2019 to 1 Jul 2020.
    • 12 Dec 2017 Results (n=12) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top